Related Experiment Video
Updated: Mar 9, 2026
A Neurite Outgrowth Assay and Neurotoxicity Assessment with Human Neural Progenitor Cell-Derived Neurons
Published on: August 6, 2020
Deep Phosphoproteomic Measurements Pinpointing Drug Induced Protective Mechanisms in Neuronal Cells
Chengli Yu1, Jing Gao2, Yanting Zhou3
1Department of Analytical Chemistry and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of SciencesShanghai, China; College of Pharmacy, University of Chinese Academy of Sciences, Chinese Academy of SciencesBeijing, China.
GFKP-19, a novel compound, shows neuroprotective effects against Alzheimer's disease by reversing Aβ₂₅-₃₅-induced phosphorylation changes. It may reduce oxidative stress and tau phosphorylation, offering potential therapeutic mechanisms.
Area of Science:
- Neuroscience
- Proteomics
- Pharmacology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder significantly impacting quality of life.
- GFKP-19, a 2-pyrrolidone derivative, demonstrates memory-enhancing effects in mice with dysmnesia.
- The precise molecular mechanisms of neuroprotective compounds like GFKP-19 require elucidation.
Purpose of the Study:
- To establish and validate a deep quantitative phosphoproteomic approach for analyzing drug effects in neurodegenerative disease models.
- To investigate the molecular mechanisms underlying the neuroprotective effects of GFKP-19 in Alzheimer's disease.
Main Methods:
- Utilized triple SILAC (Stable Isotope Labeling by Amino acids in Cell culture) labeling for quantitative phosphoproteomics.
- Analyzed deep quantitative phosphoproteome of neuro-2a cells treated with and without GFKP-19 and Aβ₂₅-₃₅.
- Employed high-resolution mass spectrometry to quantify phosphosites.
Main Results:
- Quantified 14,761 Class I phosphosites across control, damaged, and protected conditions with high reproducibility.
- Demonstrated that GFKP-19 reverses Aβ₂₅-₃₅-induced phosphorylation changes in neuro-2a cells.
- Identified potential mechanisms: downregulation of NOS1 phosphorylation at S847 (reducing oxidative stress/inflammation) and MAPK14 phosphorylation at T180 (reducing tau phosphorylation).
Conclusions:
- GFKP-19 exhibits neuroprotective potential against Alzheimer's disease pathology.
- The study establishes a robust phosphoproteomic method for drug mechanism studies.
- GFKP-19 may offer dual protection by mitigating oxidative damage and reducing tau hyperphosphorylation.
